All treatments
Treatment
Comirnaty JN.1 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine clinical trials
2 indexed studies · 0 currently recruiting
- AuthorisedTherapeutic use (Phase IV)
LONGITUDINAL FOLLOW-UP OF SARS-COV-2 IMMUNITY IN IMMUNOCOMPROMISED POPULATIONS IN BELGIUM (COVICO) A non-commercial multicenter academic prospective cohort study during 2023-2026
This study looks at how well COVID-19 vaccines boost immunity in people with weakened immune systems and healthy individuals in Belgium. Researchers will check antibody levels three times a year to understand protection against new virus variants. It aims to help us better protect vulnerable groups.
For: Healthy persons and immunocompromised patients (nursing home residents · dialysis patients and kidney- and lung transplant patients) from age 18 till age 105Belgium - Ongoing, recruitingTherapeutic use (Phase IV)
A phase 4, open-label study to evaluate the short-term innate immune response after administration of a COVID-19 mRNA vaccine (Comirnaty JN.1®) in healthy adults aged 18 to 40 years.
This study looks at how a new COVID-19 vaccine (Comirnaty JN.1) affects the body's immediate protections. Researchers want to see changes in immune markers shortly after vaccination in healthy adults aged 18 to 40.
For: COVID-19Belgium